Using deep sequencing, human immunodeficiency virus (HIV) resistance-associated mutations were detected as minority species in the cerebrospinal fluid (CSF) of 4 patients with higher HIV type 1 RNA load in CSF than in plasma, but not in 2 patients with higher plasma viral load. Deep sequencing could help our understanding of viral escape in the central nervous system.
Combination antiretroviral therapy (ART) is highly effective in the suppression of human immunodeficiency virus type 1 (HIV-1) replication. However, recent reports have highlighted the possibility of viral escape in the central nervous system (CNS) [1] [2] [3] , which is believed to be due to compartmentalization [4] . Other studies have found evidence of a greater diversity of viral strains in cerebrospinal fluid (CSF) [5] , which may harbor resistance-associated mutations (RAMs) [1, 2] . The lack of penetration of some antiretroviral agents into the CNS was postulated to account for this phenomenon [6] , although this hypothesis is controversial [7] [8] [9] [10] . The cause and significance of CNS viral escape remains poorly understood [6] .
Most studies analyzing HIV strains in CSF are dependent on conventional Sanger sequencing. Minority viral species representing <20% of the population may not be detected. Nextgeneration or deep sequencing is capable of analyzing viral sequences in greater detail [11, 12] and could provide insight into the mechanisms of viral escape. Here, we used a benchtop deep sequencing platform (454 GS Junior, Roche, Switzerland) to study CSF/plasma sample pairs in 6 patients.
METHODS

Patients and Samples
Residual CSF and plasma samples from HIV-1-infected patients submitted to 2 London virology laboratories between 2012 and 2014 were retrospectively studied. Only those with detectable viral load in both plasma and CSF were selected. Because most samples, particularly CSF, were exhausted after standard investigations, only 6 CSF/plasma pairs were available for further deep sequencing. The characteristics, ART history, and clinical presentations of these 6 patients are listed in Table 1 .
Standard Diagnostic Tests
HIV-1 RNA load in CSF and plasma was measured using the COBAS AmpliPrep/COBAS TaqMan HIV-1 Test version 2.0 (Roche, Switzerland), in addition to other investigations such as cell count (red cells, white cells with differential), biochemistry, and culture/polymerase chain reaction (PCR) for relevant pathogens.
The reverse transcriptase (RT) and protease (PR) genes were sequenced using Sanger sequencing. ViroSeq (Abbott) was used in one of the laboratories, and an in-house method was used in the other. The sequences were submitted to the Stanford HIV genotypic resistance interpretation algorithm for analysis using the HIVdb program (http://sierra2.stanford.edu/sierra/ servlet/JSierra). Only those mutations recognized by the Stanford algorithm were considered in the analysis.
Deep Sequencing
Deep sequencing of the RT and PR genes was performed on the Roche 454 GS junior platform using the Roche HIV 454 genotyping kit. In brief, samples were centrifuged at 21 100g for 1 hour at 4°C and RNA extracted using the QIAamp Viral RNA Mini Kit (Qiagen). Viral RNA was subjected to a 2-step RT-PCR amplification, and DNA amplicons were purified, quantitated, and pooled following the manufacturer's instructions. The pooled HIV-1 amplicons were amplified by emulsion PCR and sequenced using the Roche Junior 454 instrument. HIV-1 DNA sequences were analyzed and percentage HIV variants calculated using GS Amplicon Variant Analyser software (Roche) with variant filter values set at 1%. As with the Sanger method, only those mutations recognized by the Stanford algorithm were considered. Minority species that constituted <1% of the population were not included in the analysis. The sequences obtained from deep sequencing in both CSFand plasma were compared with those obtained with Sanger sequencing.
RESULTS
All 6 patients were treatment experienced. The antiretroviral agents ever used are listed in Table 1 . Lumbar puncture was performed in all cases because of the presence of neurological symptoms. CSF viral load was compared to the plasma viral load taken at the nearest time point. Apart from patient 4, all CSF samples showed a significant lymphocytic pleocytosis; 4 patients had raised CSF protein (>0.5 g/L). Patients 1-4 had a significantly higher (>1.0 log 10 ) CSF HIV-1 RNA load compared with plasma (mean, 1.87 [range, 1.28-2.79] log 10 higher), whereas the CSF viral loads in patients 5 and 6 were lower than plasma. All 6 patients had magnetic resonance imaging (MRI) of the brain. The presence of white matter signal changes suggestive of HIV encephalopathy was reported in patients 1-5. The MRI of patient 6 showed encephalomalacia and volume loss but no signal changes.
The plasma viral load of patient 4 was too low (47 copies/mL) to allow successful sequencing by either Sanger or deep sequencing. Sequencing was successful for all other samples by both methods. Apart from 1 minor mutation (Q58E in patient 4) detected only by Sanger sequencing and a discrepancy in the mutation M184V or M184I in a plasma sample (patient 2), all the mutations identified by the Sanger method in plasma or CSF were also detected by deep sequencing. Deep sequencing did, however, identify a number of additional mutations not detected by the Sanger method, mainly in the CSF (patients 1-4) but also in plasma (patients 2 and 3). In the 2 patients (5 and 6) in whom the CSF viral load was lower than plasma, no additional mutations were detected by deep sequencing in either plasma or CSF.
The additional mutations detected by deep sequencing were mostly present as minority species, which ranged from 3% to 40.1%. In patient 1, N88S was detected in CSF at a level of 8.8%. This is likely to be selected as a result of the previous use of nelfinavir. In patient 2, both M184V and M184I were detected in CSF by Sanger sequencing. However, deep sequencing was more precise, showing that 5.9% were M184I and 94.1% M184V. The result in plasma was significantly different in that Sanger sequencing only detected M184I, whereas deep sequencing only detected M184V. In addition, minority species of mutations in PR (V82I -40.1%) and RT (D67G, K70S, 2 species of K70N) were only detected in the CSF of this patient using deep sequencing. In patient 3, the presence of K65R (CSF 2.4%) and K65N ( plasma 11.7%, CSF 7.8%) were most likely selected by tenofovir; in patient 4, detection of I47V in CSF (3%) could be related to the previous and current use of PR inhibitors including lopinavir and darunavir. A regimen change was made in patients 1-4 ( Table 1 ). The choice of antiretroviral agents in the new regimen was largely based on a perceived improvement in CNS penetration. All patients showed clinical improvement, and patient 1 had radiological improvement. Patients 5 and 6 did not have regimen change. Patient 5 was empirically treated for tuberculosis and clinically improved. Patient 6 died of an unrelated cause.
DISCUSSION
To our knowledge, this is the first study using deep sequencing to characterize HIV-1 in the CSF of patients with neurological symptoms suggestive of HIV encephalopathy. The mutations detected by deep sequencing showed good correlation with the standard Sanger method, and additional minority species in plasma and CSF were identified. The discrepancy in the M184V/I mutations and failure of the Sanger method to identify V82I at 40% in patient 2 could be due to amplification bias introduced at the PCR stage and inaccuracy of the current sequencing technology. Improved deep sequencing methods are now available and could help to address such problems.
The presence of minority species in CSF was observed only in cases where the CSF viral load was significantly higher than that of plasma. This is consistent with the compartmental theory and differential evolution of HIV-1 in the CNS. The RAMs detected in CSF were likely to be present as a result of previous or current exposure to specific ART agents; their absence in plasma could be related to a difference in drug pressure in the 2 compartments. The presence of RAMs as minority species in CSF could be due to a relative lack of CNS penetration of certain ART regimens or a result of poor adherence. A lack of drug selection pressure in CSF allows independent evolution of a full repertoire of viruses containing minority species, whereas such resistant viruses in plasma are suppressed.
In the 2 patients (5 and 6) in whom the viral loads in CSF were lower than in plasma, viral loads in both compartments were probably sustained by poor adherence, as no relevant RAMs were present. Although patient 5 had some radiological features suggestive of HIV encephalopathy, this may not be the predominant pathology, as she responded to empiric treatment for tuberculosis.
Whereas the regimen change in patients 1-4 was aimed at improving antiviral penetration to the CNS [8] , better engagement and improved adherence may have been the reason for the clinical improvement. Re-treatment using susceptible ART with good compliance should be considered. This study is limited by the small number of patients and the retrospective nature of the analysis with testing carried out at 2 different laboratories. Two of the 6 paired samples were >2 weeks apart, which may have introduced bias to the sequence analysis. Also, not all patients had radiological follow-up to confirm improvement. In addition, there were no follow-up samples to confirm the improvement in CSF viral load after the regimen change. Nevertheless, this study demonstrates the value of deep sequencing in improving our understanding of viral escape in the CNS. With improvements in sequencing technology and reduction in costs of deep sequencing, this could transform our approach to the analysis of HIV-1 sequences in different body compartments.
